Follicular Lymphoma Translocation
Follicular Lymphoma Translocation Follicular lymphoma is a type of non-Hodgkin lymphoma that arises from B-cells in the lymphatic system. An important aspect of the diagnosis and treatment of follicular lymphoma is understanding the role of genetic abnormalities, such as follicular lymphoma translocation.
Follicular lymphoma translocation refers to specific genetic rearrangements that occur within the DNA of lymphoma cells. These translocations can have a significant impact on the development, progression, and prognosis of follicular lymphoma.
Get Free Consultation
ACIBADEM Health Point: The Future of Healthcare
We believe that everyone deserves access to quality healthcare, which is why we have established multiple branches in strategic locations. Whether you're in need of routine check-ups, specialized treatments, or emergency care, ACIBADEM Health Point is here for you.One of the organizations that specializes in the diagnosis and treatment of lymphoma, including follicular lymphoma translocation, is Acibadem Healthcare Group. With their expertise in lymphoma genetics and cutting-edge treatment options, Acibadem Healthcare Group plays a crucial role in advancing our understanding of
Understanding Lymphoma Genetics
Lymphoma genetics plays a crucial role in unraveling the intricacies of this complex disease. By studying the chromosomal translocations that occur in lymphoma, researchers have gained valuable insights into the development and progression of various subtypes, including follicular lymphoma.
Chromosomal translocation in lymphoma refers to the rearrangements that happen within the genetic material of lymphocytes, leading to abnormal fusion of genes. These genetic abnormalities can have a profound impact on the behavior of lymphoma cells, influencing their growth and response to treatment.
ACIBADEM Health Point: Your Health is Our Priority!
ACIBADEM Health Point, we are dedicated to providing exceptional healthcare services to our patients. With a team of highly skilled medical professionals and state-of-the-art facilities, we strive to deliver the highest standard of care to improve the health and well-being of our patients. What sets ACIBADEM Health Point apart is our patient-centered approach. We prioritize your comfort, safety, and satisfaction throughout your healthcare journey. Our compassionate staff ensures that you receive personalized care tailored to your unique needs, making your experience with us as seamless and comfortable as possible.Lymphoma genetics research has highlighted the significance of specific translocations in the pathogenesis of follicular lymphoma. One such recurrent translocation is the t(14;18) translocation, which involves the fusion of the BCL2 gene on chromosome 18 with the immunoglobulin heavy chain gene on chromosome 14.
This translocation results in the overexpression of the BCL2 gene, which plays a critical role in evading programmed cell death, leading to the survival and accumulation of abnormal lymphoma cells. The t(14;18) translocation is found in the majority of follicular lymphoma cases and serves as a hallmark genetic abnormality for this subtype.
Understanding lymphoma genetics, particularly the chromosomal translocations that occur, provides valuable information for accurate diagnosis, prognosis, and treatment selection. By identifying specific genetic abnormalities, healthcare professionals can tailor treatment plans to target the underlying molecular drivers of lymphoma, improving patient outcomes.
The t(14;18) Translocation and BCL2 Gene Rearrangement
In the context of follicular lymphoma, one specific translocation that has garnered significant attention is the t(14;18) translocation. This translocation involves the rearrangement of the BCL2 gene, which is located on chromosome 18. The t(14;18) translocation results in the fusion of the BCL2 gene with the immunoglobulin heavy chain (IGH) gene on chromosome 14.
The BCL2 gene is known for its role in regulating apoptosis, or programmed cell death. When the BCL2 gene undergoes rearrangement due to the t(14;18) translocation, it results in overexpression of the BCL2 protein, which inhibits apoptosis, allowing lymphoma cells to survive and proliferate.
This translocation is particularly prevalent in cases of follicular lymphoma, with approximately 85-90% of patients exhibiting the t(14;18) translocation and BCL2 gene rearrangement. The presence of this translocation is not only important for the diagnosis of follicular lymphoma but also has implications for prognosis and treatment.
Implications for Diagnosis and Prognosis
The detection of the t(14;18) translocation and BCL2 gene rearrangement has become an essential diagnostic tool for identifying follicular lymphoma. By analyzing lymphoma cells obtained from a biopsy or other tissue sample, genetic tests such as fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR) can detect the presence of this translocation.
In addition to aiding in diagnosis, the t(14;18) translocation and BCL2 gene rearrangement have also been associated with certain prognostic factors. Studies have shown that patients with follicular lymphoma who have the t(14;18) translocation and BCL2 gene rearrangement may have a higher risk of disease progression and relapse compared to those without this translocation.
Potential Therapeutic Target
The t(14;18) translocation and subsequent overexpression of the BCL2 protein have prompted researchers to explore therapeutic strategies targeting this abnormality. The development of BCL2 inhibitors, such as venetoclax, has shown promising results in the treatment of follicular lymphoma with the t(14;18) translocation and BCL2 gene rearrangement.
By targeting the BCL2 protein, these inhibitors promote apoptosis and induce cell death in lymphoma cells, offering a potential personalized treatment option for patients with this specific translocation.
| Translocation | Prevalence in Follicular Lymphoma |
|---|---|
| t(14;18) | Approximately 85-90% |
Molecular Biology of Follicular Lymphoma
Follicular lymphoma is a complex disease involving various molecular processes that contribute to the growth and survival of cancerous cells. Understanding the molecular biology of follicular lymphoma is crucial for developing targeted therapies and improving patient outcomes.
One of the key mechanisms in follicular lymphoma is the dysregulation of cellular pathways involved in cell growth and division. This dysregulation is often caused by genetic abnormalities, such as chromosomal translocations, which can lead to the activation of oncogenes or the inactivation of tumor suppressor genes.
Lymphoma molecular biology studies have identified several genes and pathways that play a significant role in the development and progression of follicular lymphoma. One of the most well-known genetic abnormalities in follicular lymphoma is the t(14;18) translocation, which results in the rearrangement of the BCL2 gene.
The BCL2 gene rearrangement leads to the overexpression of the BCL2 protein, which inhibits apoptosis, or programmed cell death. This inhibition allows lymphoma cells to evade cell death and accumulate, leading to tumor formation and progression.
In addition to the t(14;18) translocation, other genetic alterations, such as mutations in genes like EZH2 and CREBBP, have been identified in follicular lymphoma. These mutations further dysregulate cellular pathways and contribute to the survival and proliferation of lymphoma cells.
Key Molecular Pathways in Follicular Lymphoma:
- B-cell receptor signaling pathway
- PI3K/AKT/mTOR pathway
- JAK/STAT pathway
- Epigenetic regulation
- Tumor microenvironment interactions
Research on lymphoma molecular biology has provided valuable insights into the underlying mechanisms of follicular lymphoma and has paved the way for the development of targeted therapies. By targeting specific molecular pathways, such as the B-cell receptor signaling pathway or the PI3K/AKT/mTOR pathway, researchers and clinicians are able to tailor treatment approaches to the individual needs of patients.
| Molecular Pathway | Targeted Therapies |
|---|---|
| B-cell receptor signaling pathway | Bruton’s tyrosine kinase (BTK) inhibitors |
| PI3K/AKT/mTOR pathway | PI3K inhibitors, mTOR inhibitors |
| JAK/STAT pathway | JAK inhibitors |
| Epigenetic regulation | EZH2 inhibitors |
| Tumor microenvironment interactions | Immune checkpoint inhibitors |
By targeting these specific molecular pathways, researchers and clinicians can improve treatment efficacy and minimize the side effects associated with traditional chemotherapy. Personalized medicine approaches that take into account the molecular biology of follicular lymphoma hold great promise for improving patient outcomes and ultimately finding a cure for this complex disease.
Impact of Follicular Lymphoma Translocation on Diagnosis
The diagnosis of follicular lymphoma can be challenging due to its similarity to other types of lymphoma. However, the identification of follicular lymphoma translocations plays a crucial role in distinguishing it from other lymphoma subtypes. These translocations are genetic abnormalities that occur in the DNA of lymphoma cells, leading to the rearrangement of specific genes like BCL2. Ultimately, the detection of follicular lymphoma translocation can provide valuable diagnostic information to healthcare professionals.
By studying the lymphoma genetics, including the presence of follicular lymphoma translocations, doctors can accurately classify the disease and provide more targeted treatment options. The identification of specific translocations associated with follicular lymphoma helps confirm the diagnosis, as these translocations are not typically found in other types of lymphoma.
Furthermore, the presence of follicular lymphoma translocations also impacts the prognosis and treatment decisions. Certain translocations are associated with a better or worse prognosis, influencing the choice of treatment and the monitoring of patients during their cancer journey. In addition, the knowledge of specific translocations allows healthcare professionals to tailor treatment strategies, such as targeted therapies, immunotherapies, or stem cell transplantations, to address the underlying genetic abnormalities driving the disease.
Examples of Follicular Lymphoma Translocations and Their Diagnostic Implications
| Translocation | Implications |
|---|---|
| t(14;18) | Frequently found in follicular lymphoma. Confirms the diagnosis of follicular lymphoma and indicates a relatively indolent disease course. |
| t(2;18) | Suggests the presence of a high-grade component, potentially indicating a higher risk or aggressive disease. |
| t(8;14) | Associated with Burkitt lymphoma. Its presence would warrant a different diagnosis and treatment approach than follicular lymphoma. |
The detection of follicular lymphoma translocation is typically performed through molecular genetic testing, such as fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR) techniques. By analyzing the DNA of lymphoma cells, these tests identify specific translocations and provide valuable information for diagnosis and treatment planning.
In conclusion, the impact of follicular lymphoma translocation on diagnosis is significant. The identification of these specific genetic abnormalities not only confirms the diagnosis of follicular lymphoma but also guides treatment decisions and prognostic evaluations. With advances in lymphoma genetics and molecular biology, the role of follicular lymphoma translocation in diagnosis and personalized medicine continues to evolve, bringing us closer to more precise and effective management of this complex disease.
Treatment Options for Follicular Lymphoma
Follicular lymphoma is a complex disease, and the treatment approach depends on several factors, including the presence of follicular lymphoma translocation. The goal of treatment is to control the disease, relieve symptoms, and improve the patient’s quality of life. Here are some of the commonly used treatment options for follicular lymphoma:
1. Watchful Waiting
In certain cases, particularly when the disease is in its early stages and not causing significant symptoms, a watchful waiting approach may be recommended. This involves regular monitoring of the disease’s progression through imaging tests such as CT scans, along with close observation of symptoms. Treatment is deferred until the disease progresses or symptoms become bothersome.
2. Chemotherapy
Chemotherapy is commonly used in the treatment of follicular lymphoma and involves the use of drugs to kill cancer cells. It can be administered as a single drug or in combination with other drugs, depending on the stage and aggressiveness of the disease. Chemotherapy can be given orally or through intravenous infusion.
3. Immunotherapy
Immunotherapy works by stimulating the body’s immune system to recognize and attack cancer cells. One type of immunotherapy used in follicular lymphoma is monoclonal antibody therapy, which targets specific proteins on the surface of cancer cells. Examples of monoclonal antibodies used in the treatment of follicular lymphoma include rituximab (Rituxan) and obinutuzumab (Gazyva).
4. Targeted Therapy
Targeted therapy is designed to specifically target cancer cells or their supporting structures, while sparing normal cells. In follicular lymphoma, targeted therapy drugs may interfere with specific signaling pathways or proteins involved in the growth and survival of cancer cells. Examples of targeted therapies used in follicular lymphoma include idelalisib (Zydelig) and venetoclax (Venclexta).
5. Radiation Therapy
Radiation therapy uses high-energy beams to kill cancer cells and is typically used in localized areas of the body affected by follicular lymphoma. It can be delivered externally (external beam radiation therapy) or internally (brachytherapy). Radiation therapy is often used alongside other treatment modalities.
6. Stem Cell Transplantation
In some cases, high-dose chemotherapy and stem cell transplantation may be recommended for patients with follicular lymphoma. This procedure involves the use of high-dose chemotherapy to kill cancer cells, followed by the infusion of healthy stem cells to restore the bone marrow. Stem cell transplantation can be autologous (using the patient’s own stem cells) or allogeneic (using stem cells from a donor).
It’s important to note that treatment decisions are individualized based on the patient’s specific circumstances and may vary from case to case. The choice of treatment depends on factors such as the stage and extent of the disease, the presence of follicular lymphoma translocation, the patient’s overall health and preferences, and the experience and expertise of the treating physician.
| Treatment Option | Description |
|---|---|
| Watchful Waiting | Regular monitoring of the disease without immediate treatment |
| Chemotherapy | Use of drugs to kill cancer cells |
| Immunotherapy | Stimulating the immune system to attack cancer cells |
| Targeted Therapy | Specifically targeting cancer cells or supporting structures |
| Radiation Therapy | Use of high-energy beams to kill cancer cells |
| Stem Cell Transplantation | High-dose chemotherapy followed by stem cell infusion |
Prognosis and Follicular Lymphoma Translocation
Follicular lymphoma translocation plays a crucial role in determining the prognosis of patients with this type of lymphoma. The specific genetic abnormalities associated with follicular lymphoma can have a significant impact on the course and outcome of the disease.
One of the key factors in understanding the prognosis of follicular lymphoma is the identification of lymphoma genetics, including the presence of follicular lymphoma translocation. By analyzing the specific translocations that occur in follicular lymphoma, healthcare professionals can gain valuable insights into the behavior of the disease and make more informed decisions regarding treatment.
Research has shown that certain translocations, such as the t(14;18) translocation and BCL2 gene rearrangement, are associated with a poorer prognosis in follicular lymphoma patients. These genetic abnormalities can lead to the overexpression of anti-apoptotic proteins, promoting the survival and growth of cancer cells.
| Translocation | Prognostic Impact |
|---|---|
| t(14;18) | Associated with a higher risk of transformation to more aggressive lymphoma subtypes |
| Other translocations | May have varying prognostic significance and require further study |
However, it’s important to note that prognosis is influenced by multiple factors, and the presence of follicular lymphoma translocation alone cannot determine the outcome of an individual patient. Other factors, such as the stage of the disease, patient age, and overall health, also play significant roles in prognosis.
Advancements in lymphoma genetics and the understanding of follicular lymphoma translocation continue to provide valuable insights into prognosis prediction. By combining these genetic factors with clinical information, healthcare professionals can develop more personalized treatment plans tailored to each patient’s specific needs. Follicular Lymphoma Translocation
Overall, the impact of follicular lymphoma translocation on prognosis highlights the importance of comprehensive genetic testing and individualized treatment approaches for patients with follicular lymphoma.
The Role of Acibadem Healthcare Group in Research and Treatment
The Acibadem Healthcare Group plays a crucial role in advancing both research and treatment options for lymphoma patients, including those with follicular lymphoma translocations. With a commitment to excellence in healthcare, Acibadem is at the forefront of cutting-edge discoveries and innovative therapies.
As a leader in the field, Acibadem Healthcare Group actively contributes to the understanding of lymphoma genetics, continuously striving to uncover new insights into the underlying mechanisms of the disease. This extensive research enables the development of personalized treatment strategies that target specific genetic abnormalities, including follicular lymphoma translocations.
Moreover, Acibadem provides a wide range of treatment options for lymphoma patients, tailored to their unique needs and genetic profiles. The multidisciplinary team of experts at Acibadem works collaboratively to design individualized treatment plans, integrating the latest advancements in lymphoma care.
The dedication of Acibadem Healthcare Group to lymphoma research and treatment has resulted in significant improvements in patient outcomes and quality of life. Through their comprehensive approach, they have transformed the way lymphomas are diagnosed, managed, and treated.
For more information about the Acibadem Healthcare Group, their expertise in lymphoma genetics, and the advanced treatment options they offer, please visit their official website.
Advances in Understanding Follicular Lymphoma Translocation
Recent research has contributed to significant advances in understanding follicular lymphoma translocation, shedding light on the molecular biology of this complex disease. These findings have the potential to revolutionize the diagnosis and treatment of follicular lymphoma, offering new hope to patients and healthcare professionals alike.
Unraveling the Genetic Factors
Studies focusing on lymphoma molecular biology have revealed crucial insights into the genetic factors underlying follicular lymphoma translocation. By analyzing the intricate chromosomal rearrangements involved in this disease, researchers have gained a deeper understanding of the mechanisms driving its development and progression.
Of particular interest is the identification of specific genetic alterations, such as the t(14;18) translocation and BCL2 gene rearrangement, which are known to play a pivotal role in follicular lymphoma. These discoveries have not only expanded our knowledge of the disease but also paved the way for targeted therapeutic approaches.
Emerging Research Directions
New avenues of research are continuously being explored to unravel the complexities of follicular lymphoma translocation. The field of lymphoma molecular biology is witnessing exciting developments, including groundbreaking studies on the impact of microRNAs and epigenetic modifications on the disease’s pathogenesis.
Furthermore, advancements in genomic profiling techniques enable the detailed analysis of follicular lymphoma translocations, aiding in the identification of potential therapeutic targets and prognostic markers. These advancements hold promising implications for personalized medicine and the development of innovative treatment strategies.
Fostering Collaboration and Knowledge-sharing
Recognizing the significance of understanding follicular lymphoma translocation, researchers, clinicians, and healthcare institutions worldwide are collaborating to foster knowledge-sharing and drive progress in the field. These collaborative efforts have resulted in an exponential increase in the volume of research, with each study contributing valuable insights that further enrich our understanding of the disease.
The exchange of knowledge and expertise through conferences, symposiums, and scientific publications empowers the medical community to explore new frontiers and push the boundaries of follicular lymphoma research. As a result, we are witnessing an unprecedented evolution in our understanding of this complex disease.
| Advancements in Understanding Follicular Lymphoma Translocation | Impact |
|---|---|
| Identification of specific genetic alterations | Enhanced diagnostic accuracy and targeted treatment options |
| Research on microRNAs and epigenetic modifications | Potential for novel therapeutic approaches |
| Expanded genomic profiling techniques | Improved identification of therapeutic targets and prognostic markers |
| Increased collaboration and knowledge-sharing | Rapid advancements in understanding follicular lymphoma |
Personalized Medicine and Follicular Lymphoma Translocation
In the realm of lymphoma treatment, personalized medicine has emerged as a promising approach, particularly in the context of follicular lymphoma translocation. By tailoring treatment plans based on the specific translocations present in an individual’s cancer cells, healthcare professionals can optimize therapy to improve patient outcomes.
Traditionally, lymphoma treatment options have focused on generalized approaches that may not take into account the unique genetic characteristics of each patient’s cancer. However, with advancements in our understanding of follicular lymphoma translocation, we can now identify specific genetic abnormalities and design treatment regimens tailored to address them.
Through comprehensive genetic testing, oncologists can determine the presence of follicular lymphoma translocations and identify the genes involved. Armed with this knowledge, they can then prescribe targeted therapies that directly inhibit the aberrant genes or signaling pathways driving tumor growth.
One example of personalized medicine in follicular lymphoma involves the use of monoclonal antibodies, such as rituximab, which specifically target CD20, a protein found on the surface of cancer cells. This targeted therapy, when combined with standard chemotherapy, has shown improved outcomes in patients with
Table: Examples of Personalized Medicine Approaches for Follicular Lymphoma Translocation
| Treatment Approach | Description |
|---|---|
| Monoclonal Antibodies | Target specific proteins on cancer cells, leading to enhanced therapeutic efficacy. |
| Small Molecule Inhibitors | Block abnormal molecular pathways, inhibiting tumor growth. |
| Immunotherapies | Stimulate the patient’s immune system to recognize and destroy lymphoma cells. |
It is important to note that personalized medicine approaches for follicular lymphoma translocation are still evolving, and ongoing research is crucial for further advancements in treatment efficacy. By continuing to investigate the intricacies of lymphoma genetics and molecular biology, we can refine personalized medicine strategies and make continuous strides towards better outcomes for patients.
In conclusion, personalized medicine offers a promising avenue for improving treatment outcomes in patients with follicular lymphoma translocation. By identifying the specific genetic abnormalities and tailoring therapies accordingly, healthcare professionals can optimize treatment plans and provide more targeted and effective care.
Future Directions and Research Opportunities
As our understanding of continues to evolve, there are exciting future directions and research opportunities that hold significant promise in improving the diagnosis, treatment, and prognosis of this disease.
One key area of focus is lymphoma genetics, which plays a crucial role in unraveling the complex molecular underpinnings of follicular lymphoma. By studying the genetic abnormalities associated with the disease, researchers can gain valuable insights into the mechanisms driving its development and progression. This knowledge can pave the way for targeted therapies and personalized medicine approaches that specifically target the genetic alterations contributing to follicular lymphoma.
Advancements in lymphoma molecular biology also present promising avenues for further investigation. Understanding the intricate molecular pathways involved in follicular lymphoma can uncover novel therapeutic targets and potential biomarkers for early detection and monitoring of the disease.
Furthermore, studying the correlation between follicular lymphoma translocation and prognosis is of utmost importance. Identifying specific translocations that are associated with more favorable or unfavorable outcomes can help clinicians tailor treatment plans and provide more accurate prognostic information to patients.
Overall, ongoing research efforts in follicular lymphoma translocation, lymphoma genetics, and lymphoma molecular biology are crucial for advancing our knowledge and improving patient outcomes. By investing in these future directions and embracing the research opportunities they offer, we can make significant strides toward a better understanding and management of this complex disease.
FAQ
What is follicular lymphoma translocation?
Follicular lymphoma translocation is a genetic abnormality that occurs in follicular lymphoma, a type of non-Hodgkin lymphoma. It involves the rearrangement of specific chromosomes, leading to the activation of oncogenes and the inhibition of tumor suppressor genes.
How does follicular lymphoma translocation affect lymphoma genetics?
Follicular lymphoma translocation is a key component of lymphoma genetics. It contributes to the development and progression of follicular lymphoma by altering the expression of genes and disrupting normal cellular functions.
What is the significance of the t(14;18) translocation and BCL2 gene rearrangement in follicular lymphoma?
The t(14;18) translocation and BCL2 gene rearrangement are specific forms of follicular lymphoma translocation. This translocation results in the overexpression of the BCL2 gene, which prevents programmed cell death (apoptosis) and contributes to the survival and proliferation of lymphoma cells.
What is the molecular biology of follicular lymphoma?
The molecular biology of follicular lymphoma involves aberrant signaling pathways, dysregulated gene expression, and disrupted cellular processes. These molecular abnormalities contribute to the survival, proliferation, and resistance to treatment of follicular lymphoma cells.
How does follicular lymphoma translocation impact the diagnosis of the disease?
Follicular lymphoma translocation plays a crucial role in diagnosing the disease. Identifying specific translocations can aid in distinguishing follicular lymphoma from other types of lymphoma and inform treatment decisions.
What treatment options are available for follicular lymphoma?
Treatment options for follicular lymphoma include watchful waiting, chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation. The choice of treatment depends on factors such as the stage of the disease, the patient's overall health, and specific genetic abnormalities, including follicular lymphoma translocations.
How does follicular lymphoma translocation affect the prognosis?
Follicular lymphoma translocation can impact the prognosis of the disease. Specific translocations can influence disease progression, treatment response, and overall survival in follicular lymphoma patients.
Acibadem Healthcare Group is a renowned healthcare organization that may specialize in research and advanced treatment options for lymphoma, including follicular lymphoma translocation. They contribute to cutting-edge research and provide comprehensive care for lymphoma patients.
What are the recent advances in understanding follicular lymphoma translocation?
Recent advances in understanding follicular lymphoma translocation include the identification of new genetic abnormalities, the development of targeted therapies, and the exploration of novel treatment strategies based on individual genetic profiles.
How does personalized medicine relate to follicular lymphoma translocation?
Personalized medicine holds promise in the context of follicular lymphoma translocation. Tailoring treatment based on specific translocations can optimize therapy efficacy, minimize side effects, and improve patient outcomes.
What are the future directions and research opportunities in follicular lymphoma translocation?
Future directions and research opportunities in follicular lymphoma translocation include further investigation into the genetic and molecular aspects of the disease, the development of targeted therapies, and the exploration of novel prognostic factors to refine diagnosis and treatment strategies.
ACIBADEM Healthcare Group Hospitals and Clinics
With a network of hospitals and clinics across 5 countries, including 40 hospitals, ACIBADEM Healthcare Group has a global presence that allows us to provide comprehensive healthcare services to patients from around the world. With over 25,000 dedicated employees, we have the expertise and resources to deliver unparalleled healthcare experiences. Our mission is to ensure that each patient receives the best possible care, supported by our commitment to healthcare excellence and international healthcare standards. Ready to take the first step towards a healthier future? Contact us now to schedule your Free Consultation Health session. Our friendly team is eager to assist you and provide the guidance you need to make informed decisions about your well-being. Click To Call Now !*The information on our website is not intended to direct people to diagnosis and treatment. Do not carry out all your diagnosis and treatment procedures without consulting your doctor. The contents do not contain information about the therapeutic health services of ACIBADEM Health Group.